Results 51 to 60 of about 120,528 (253)
BMC Cancer, 2019 Background Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and ...
Joshua P. Schiff +6 more
doaj +1 more source
Prostate Specific Antigen (PSA): The Historical Perspective
McGill Journal of Medicine, 2020 In 1970, shortly after joining Roswell Park Memorial Institute, the New York State institute for the study of malignant diseases, the author initiated investigations on the use of tumor cell products for diagnosis and therapy of cancer.
T. Ming Chu
doaj +1 more source
An investigation into minichromosomal maintenance proteins (MCMs) for the diagnosis of prostate cancer, as a possible alternative to prostate specific antigen (PSA) [PDF]
, 2005 The current strategy for the diagnosis of prostate cancer includes serum prostate specific antigen (PSA) measurement. There is however debate into its specificity and sensitivity, so new diagnostic markers are under investigation.
Watkins, Jane Louise
core
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
Beyond the Number: Interpreting Prostate-Specific Antigen Elevation in the Context of Prostate Inflammation [PDF]
Urogenital Tract InfectionProstate-specific antigen (PSA) is indispensable but not cancer specific; inflammation, benign prostatic hyperplasia, urinary retention, ejaculation, and instrumentation can all elevate PSA and complicate cancer risk assessment.
Byoungkyu Han, Ki-Hyuck Moon
doaj +1 more source
Molecular Oncology, EarlyView.CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak +10 more
wiley +1 more source
Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases
Asian Journal of Surgery, 2005 To review the pattern of initial clinical manifestation of patients who present with biochemically-advanced prostate carcinoma. Methods: A review of 39 prostate cancer patients with initial prostate specific antigen (PSA) levels of more than 400 ng/mL ...
Edmund Chiong +3 more
doaj +1 more source
European Urology Open Science, 2021 Prostate-specific antigen (PSA) density is an established prognostic marker for prostate cancer. We investigated whether the inclusion of PSA density or prostate volume in the Memorial Sloan Kettering Cancer Center nomograms improves the prediction of ...
Michael Tzeng +7 more
doaj +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth
, 2006 PURPOSE: The antiproliferative effects of pharmacological agents used for androgen ablative therapy in prostate cancer, including goserelin, bicalutamide and cyproterone acetate (Fluka Chemie, Buchs, Switzerland), were tested in vitro.
Peternac, Daniel +4 more
core +1 more source